



ARTÍCULO ORIGINAL

## Evaluation of variants in *IL6R*, *TLR3*, and *DC-SIGN* genes associated with dengue in a sampled Colombian population

Efrén Avendaño-Tamayo<sup>1,2</sup>, Alex Rúa<sup>2</sup>, María Victoria Parra-Marín<sup>1,2</sup>, Winston Rojas<sup>1</sup>, Omer Campo<sup>1</sup>, Juan Chacón-Duque<sup>1</sup>, Piedad Agudelo-Flórez<sup>3</sup>, Carlos F. Narváez<sup>4</sup>, Doris M. Salgado<sup>5</sup>, Bertha Nelly Restrepo<sup>6</sup>, Gabriel Bedoya<sup>1</sup>

<sup>1</sup> Laboratorio de Genética Molecular, Universidad de Antioquia, Medellín, Colombia

<sup>2</sup> Grupo de Investigación en Ciencias Básicas Aplicadas, Tecnológico de Antioquia, Medellín, Colombia

<sup>3</sup> Escuela de Graduados, Universidad CES, Medellín, Colombia

<sup>4</sup> Programa de Medicina, Facultad de Salud, Universidad Surcolombiana, Neiva, Colombia

<sup>5</sup> Unidad de Infectología Pediátrica, Hospital Universitario de Neiva, Neiva, Colombia

<sup>6</sup> Instituto Colombiano de Medicina Tropical, Universidad CES, Sabaneta, Colombia

**Introduction:** Host genetics is recognized as an influential factor for the development of dengue disease.

**Objective:** This study evaluated the association of dengue with the polymorphisms rs8192284 for gene *IL6R*, rs3775290 for *TLR3*, and rs7248637 for *DC-SIGN*.

**Materials and methods:** Of the 292 surveyed subjects, 191 were confirmed for dengue fever and the remaining 101 were included as controls. The genotypes were resolved using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). In an attempt to determine the risk (Odds Ratio) of suffering dengue fever, data were analyzed using chi-square for alleles and logistic regression for both genotypes and allelic combinations. Confidence intervals were set to 95% for all tests regardless of the adjustment by either self-identification or ancestry.

**Results:** For Afro-Colombians, the allele rs8192284 C offered protection against dengue [OR=0.425, (0.204-0.887), p=0.020]. The alleles rs7248637 A and rs3775290 A posed, respectively, an increased risk of dengue for Afro-Colombians [OR=2.389, (1.170-4.879), p=0.015] and *Mestizos* [OR=2.329, (1.283-4.226), p=0.005]. The reproducibility for rs8192284 C/C [OR=2.45, (1.05-5.76), p=0.013] remained after adjustment by Amerindian ancestry [OR=2.52, (1.04-6.09), p=0.013]. The reproducibility for rs3775290 A/A [OR=2.48, (1.09-5.65), p=0.033] remained after adjustment by European [OR=2.34, (1.02-5.35), p=0.048], Amerindian [OR=2.49, (1.09-5.66), p=0.035], and African ancestry [OR=2.37, (1.04-5.41), p=0.046]. Finally, the association of dengue fever with the allelic combination CAG [OR=2.07, (1.06-4.05), p=0.033] remained after adjustment by Amerindian ancestry [OR=2.16, (1.09-4.28), p=0.028].

**Conclusions:** Polymorphisms rs8192284 for *IL6R*, rs3775290 for *TLR3*, and rs7248637 for *DC-SIGN* were associated with the susceptibility to suffer dengue fever in the sampled Colombian population.

**Key words:** Dengue/genetics; toll-like receptor 3; polymorphism, genetic; Colombia

### Evaluación de las variantes en los genes *IL6R*, *TLR3* y *DC-SIGN* asociadas con dengue en una muestra de población colombiana

**Introducción.** La genética del huésped se reconoce como un factor que influye en el desarrollo del dengue.

**Objetivo.** Este estudio evaluó la asociación del dengue con los polimorfismos rs8192284 del gen *IL6R*, rs3775290 del *TLR3* y rs7248637 del *DC-SIGN*.

**Materiales y métodos.** De los 292 sujetos encuestados, en 191 se confirmó la presencia de fiebre por dengue y los restantes 101 se incluyeron como controles. Los genotipos se resolvieron mediante reacción en cadena de la polimerasa y polimorfismos en la longitud de los fragmentos de restricción (PCR-RFLP). En un intento por determinar el riesgo de sufrir dengue, los datos se analizaron mediante la prueba de ji al cuadrado para los alelos y la regresión logística para los genotipos y las combinaciones alélicas. Los intervalos de confianza se calcularon a 95 % para todas las pruebas independientemente ajustadas por autoidentificación o componente genético ancestral.

**Resultados.** En los afrocolombianos, el alelo C rs8192284 ofreció protección contra el dengue (OR=0,425; 0,204-0,887, p=0,020). Los alelos A rs7248637 y A rs3775290

**Received:** 13/09/17

**Accepted:** 02/08/18

**Published:** 03/08/18

**Citation:**

Avendaño-Tamayo E, Rúa A, Parra-Marín M, Rojas W, Campo O, Chacón-Duque J, Agudelo-Flórez P, Narváez C, Salgado D, Restrepo B, Bedoya G. Evaluación de variantes en los genes *IL6R*, *TLR3* y *DC-SIGN* asociadas con dengue en una población colombiana muestreada. *Biomédica*. 2018;39:88-101 <https://doi.org/10.7705/biomedica.v39i1.4029>

**Corresponding author:**

Efrén Avendaño, Instituto de Biología, Universidad de Antioquia, Calle 70 N° 52-21, Medellín, Colombia  
Telephone number: (574) 304 592 2265; fax: (574) 219 6469  
efren44at@gmail.com

**Author contribution:**

All authors significantly contributed to the present study from the proposal stage to the manuscript edition. They participated in the sampling, analysis, and interpretation of the data. They were all involved in the experimental design and the manuscript writing until consensus was reached. Therefore, all are responsible for every aspect pertaining to the submitted manuscript in its present form.

**Funding:**

This research benefited from a grant from Colciencias in the framework of projects 325634319263 and 111549326145. It was also partly funded by Institución Universitaria Tecnológico de Antioquia through a project under Code 206001125.

**Conflicts of interest:**

The authors declare no conflicts of interest. Sponsors did not take part in the analysis or interpretation of the data.

plantearon un mayor riesgo de dengue para los afrocolombianos (OR=2,389; 1,170-4,879; p=0,015) y los mestizos (OR=2,329; 1,283-4,226; p=0,005), respectivamente. La reproducibilidad para rs8192284 C/C (OR=2,45; 1,05-5,76; p=0,013) permaneció después del ajuste por el componente genético ancestral amerindio (OR=2,52; 1,04-6,09; p=0,013). La reproducibilidad del rs3775290 A/A (OR=2,48; 1,09-5,65; p=0,033) permaneció después del ajuste por el componente europeo (OR=2,34; 1,02-5,35; p=0,048), el amerindio (OR=2,49; 1,09- 5,66; p=0,035), y el africano (OR=2,37; 1,04-5,41; p=0,046). Por último, la asociación del dengue con la combinación alélica CAG (OR=2,07; 1,06-4,05; p=0,033) permaneció después del ajuste por el componente genético amerindio (OR=2,16; 1,09-4,28; p=0,028).

**Conclusión.** Los polimorfismos rs8192284 en *IL6R*, rs3775290 en *TLR3* y rs7248637 en *DC-SIGN*, se asociaron con la propensión a sufrir dengue en una muestra de población colombiana.

**Palabras clave:** dengue/genética; receptor toll-like 3; polimorfismo genético; Colombia.

Dengue virus (DENV) infection may cause acute systemic diseases. From a number of dengue not-licensed vaccines, the one named CYD-TDV has been recently approved by the World Health Organization (WHO) (1). The CYD-TDV has proven efficacy against confirmed cases in endemic countries of the Americas such as Brazil and México (2) but DENV continues to spread (3,4) widely in Colombia (5). From the 50 to 100 million infection cases estimated worldwide annually (6), roughly 1.5 million occur in Colombia (3).

Dengue can adopt three clinical forms: Self-limited dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Patients diagnosed with DF present with high fever for two to seven days accompanied by at least two mild hemorrhagic manifestations such as gingival bleeding, petechiae and the like (6), and/or pain (headache, retro-orbital pain, myalgia, or arthralgia, among others). DHF comprises very high fever, hemorrhagic trends, hepatomegaly, or extravasation (thrombocytopenia and/or pleural effusion). Finally, DSS produces a homeostatic alteration characterized by an undetectable pulse before death in DHF/DSS (6-8).

DENV infection has a specific set of mechanisms. Dendritic cells are the first population DENV attaches to (9). DENV binds to the dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) thanks to the E protein on the DENV surface. There is substantial evidence that DC-SIGN is involved with dengue disease development (10,11). Upon DENV infection, pro-inflammatory cytokines that are produced via DC-SIGN may cause apoptosis when patients display cross-reactivity between both platelets and viral antigens (12-15). Some of these cytokines are interleukin-6 and interleukin-8. Interleukin-6 triggers inflammation and activates a wide range of different cells (16). According to Marín, *et al.*, (17) interleukin-6 also induces pro-inflammatory molecules like the interleukin-6-receptor (IL6R) and its soluble isoform (sIL6R). This receptor is expressed by neutrophils and CD4 T-cells (16).

The intercellular mechanisms of DENV infection show patterns associated with pathogens that foster its development and propagation. The intracellular domain of DC-SIGN drives signaling activation of toll-like receptors (TLR), which allow identification of molecular patterns associated with pathogens (9). TLRs activate protection mechanisms and mediate the onset of innate immune effectors (18).

The activation of the toll-like receptor 3 (TLR3) inhibits DENV replication in monocytes *in vitro* resulting in antiviral potential through interferons (18,19).

Although this activation follows direct binding between TLR3 and intermediate double-stranded RNA (dsRNA) from DENV, the conformation of this intermediate dsRNA is essential for DENV replication (7). The latter explains, to some extent, why expression levels of TLR3 among dengue patients are higher than in healthy ones (18).

*DC-SIGN* is on the nineteenth chromosome in a region of complex alternative splicing sites that generate soluble, membrane-associated, and truncated isoforms (9). Many variants of *DC-SIGN* have been evaluated for their association with dengue (20) with positive results for some variants within the gene (21). For instance, the SNP rs4804803, allele G, and genotype G/G are highly conspicuous allelic variants found in studies of dengue for the SNP of the rs735239, rs4804803, and rs2287886 located in the *DC-SIGN* promotor (9). In addition, the haplotype AAG is comprised by the SNPs rs735239-rs4804803-rs2287886 in synteny (9). However, these SNPs are not considered allelic combinations as they are located in the same chromosome.

*TLR3* is on the fourth chromosome and encodes the TLR3 protein, a major effector of immune responses to viral pathogens (18,22). *TLR3* is found on the surface of the endoplasmic reticulum, endosomes, lysosomes, and endolysosomes (23). The role assessment of *TLR3* variants in dengue physiopathology found that the T of SNP rs3775291 is involved not only in disease development but also in its severity (24). Indeed, the frequency of this variant was significantly lower among confirmed DHF cases than healthy controls in India. The polymorphism rs3775291 affects the protein structure and its frequency amounts to 30% between populations with European and Asian ancestry, but not in Africans (25). The 412Phe allele reduced the activation rate in several diseases, such as myocarditis and nasopharyngeal carcinomas, in response to viral infection (22).


The *IL6R* gene is on the first chromosome and encodes the IL6R/sIL6R isoforms. The sIL6R is produced by alternative splicing at the first exon, right on the rs8192284 variant and by proteolysis of membrane IL6R with the protease ADAM17 (26). ADAM17 recognizes the substitution Asp358Ala rs8192284 C, formerly named rs2228145 (27). The sIL6R is a multifunctional cytokine essential for the immune response, hematopoiesis, and acute phase reactions. It acts via a heterodimeric receptor of proteins. The expression of interleukin-6 is triggered 100-1,000 times when linked with both IL6R and glycoprotein 130 on the membrane (28). The expression of gp130 is a phenomenon known as interleukin-6 trans-signaling. High levels of sIL6R have been observed in HIV-positive patients vs healthy controls (29).

The genetic variants *IL6R*, *TLR3*, and *DC-SIGN* could actually be used as markers for both susceptibility and prognosis of dengue (20-22,24-27,30). In a context of ancestry mixture, determining the association of these variants with dengue in the Colombian population is non-existent. However, the risk of dengue could be modulated by these variants depending on the ancestry context for specific ethnic groups (31). In this context, our study aimed at establishing the extent to which dengue associated with the genetic variants considered here. To the best of our knowledge, ancestry has not been yet considered in the association between dengue and genetic variants in Colombia. This study evaluated these associations in a sample of Colombian population and the variants in three polymorphisms from three genes of immune sensors.

## Materials and methods

### *Study samples and diagnosis of dengue infection*

In an attempt to collect genetically diverse samples, 292 subjects were selected from patients at healthcare institutions from two Colombian departments: Antioquia and Chocó (figure 1). As a matter of fact, these subjects guaranteed varying ancestry in these two locations (31,32). All subjects were over 15 years old and recruited during several dengue outbreaks between July, 2009, and December, 2012. Peripheral blood samples (5 ml) were taken after getting the informed consent from all subjects.



**Figure 1.** Location of the ten healthcare institutions where subjects were recruited

The study protocol was approved by the ethics committee at *Universidad de Antioquia* in June, 2009 (code number 09-12-225). The serum samples were readily centrifuged and kept in frozen storage ( $-70^{\circ}\text{C}$ ) prior to analysis. The subjects were split into two groups: Controls and cases hinging upon confirmation of dengue as proposed by WHO (6,8). The control group was comprised of 101 subjects without prior records of dengue. Additionally, all subjects in the control group tested negative in the ELISA IgM specific for DENV.

DENV infection in the 191 subjects comprising the case group was confirmed through at least one out of three tests: Enzyme-linked immunosorbent assays ELISA IgM, IgM seroconversion, or reverse

transcription polymerase chain reaction (RT-PCR) (table 1). These techniques are detailed by WHO (1997, 2009) (6,8). In short, DENV infection was positively confirmed in 157 samples by the specific IgM antibodies (ELISA Dengue IgM Panbio, Sinnamon Park, Australia) during its acute phase. Sampling was then repeated 15 days later during the convalescent phase, and IgM seroconversion was detected in 30 subjects. Five subjects were not sampled during the convalescent phase.

**Table 1.** Diagnosis and demographics of the subjects

Parameter	Detail	Count	Percentage
ELISA IgM1 <sup>1</sup>	Positive	157	53.8
	Negative	101	34.5
IgM seroconversion	Positive	30	10.2
RT-PCR	Positive	4	1.5
Self-identification	Mestizo	162	55.3
	Afro-Colombian	130	44.7
Gender	Male	142	48.5
	Female	150	51.5
Age	Average $\pm$ SD	25 $\pm$ 15.8	-

<sup>1</sup> These blood samples were taken during the acute phase of dengue. Two hundred and ninety two aliquots of blood (one from each participant) were used for DNA extraction, then DNA was destined for variants typing in candidate genes, and ancestry-informative markers.

Finally, four more cases were confirmed by testing DENV infection in 45 subjects following the protocol defined by Lanciotti, *et al.* (1992) as adapted by Harris, *et al.* (1998) and modified by Restrepo, *et al.* (2012) (33-35). The evolution of the symptoms in these latter subjects was of less than five days. None of the subjects suffered from malaria (thick drop smear). Self-identification served for classifying the subjects as Afro-Colombians or *Mestizos*.

DNA was isolated from the blood samples following a standard phenol-chloroform protocol (36). Specific genomic regions were amplified through PCR using primers. The ancestry-informative markers (AIMs), its deltas, i.e., allele frequencies reported for ancestral populations, and meticulous typing conditions that were used in this study have been previously detailed (31). The 30 selected AIMs displayed the highest deltas, which in turn were assessed pairwise among the three ancestral populations (European, Amerindian, and African) (37). The distribution of those AIMs throughout the genome is certainly wide.

Most of these AIMs in the battery of polymorphisms of insertion/deletion and restriction fragment length (RFLP) were resolved using an ABI Prism® 310 Genetic Analyzer (Perkin Elmer-Applied Biosystems). Then, we used two primers per variant in each candidate gene: forward 5'-AGCTTGCAAATGGCCTGTTG-3' and reverse 5'-CAGAACAATGGCAATGCAGAG-3' for *IL6R*, forward 5'-GGAGCATCAGTCGTTGAAG-3' and reverse 5'-CTCAACCTAACCAAGAATAA-3' for *TLR3*, and forward 5'-AGCCAAAGCTCCTCTAGATC-3' and reverse 5'-CAGATGGGGTTTCTCCGTGTT-3' for *DC-SIGN*. One enzymatic test was performed for resolving one variant in each candidate gene. Specifically, HindIII for rs8192284 A/C<sup>1</sup>, TaqI for rs3775290 G<sup>1</sup>/A, and Hpy166II for rs7248637 G<sup>1</sup>/A (quotes indicate the cut allele). The resulting fragments were then in base pairs: 88, 182; 145, 84; and 138, 88, respectively.

## **Analysis**

First, the data on sex and age were respectively compared through chi-square and Mann-Whitney tests casting case and control groups in 2 x 2 matrixes. Then, three comparative case-control studies were conducted on the 292 subjects using alleles, genotypes, and allelic combinations as independent variables. The proportion of alleles was compared between groups using chi-square after direct counting.

Associations both of genotypes and allelic combinations were estimated by logistic regression using the SNP stat package (38); p-values <0.05 were considered significant and only the lowest were reported. Probability values (p-value), odds ratios (OR), and confidence intervals (CI) were adjusted using the individual African, Amerindian, and European ancestries as co-variables in independent regressions.

Individual ancestry from AIMs data was estimated using the Admixmap program (39). The genotypes were modeled according to inheritance (codominant, dominant, recessive, and overdominant). Genotype deviations from Hardy-Weinberg equilibrium were calculated using SNPstat package. This study focused on developing a model of fixed effects.

## **Results**

### ***Subject diagnosis and demographics***

A positive diagnosis for dengue was confirmed in 65.5% (191) of the subjects using the three tests, IgM antibody (157), IgM seroconversion (30), and RT-PCR (4) between the acute and convalescent phase (table 1). RT-PCR was performed for 45 subjects, and four tested positive. The serotypes DENV-1, -2, and -3 were identified within these four subjects and were found to be in complete agreement with those found in official reports from 2008-2009. For the location, the samples were collected according to the procedures established by Restrepo in official reports from 2008-2009 of the *Instituto Nacional de Salud* (personal communication).

Samples were taken at different times and this could be the reason for the low occurrence of viral infections (9%). For subjects tested with RT-PCR, samples were often collected after more than four days of symptoms evolution during the acute phase of dengue. This is a phase in which viremia starts diminishing, making detection of the viral genome rather complex (40). The male-female ratio was 48.5% and 51.5%, which suggests a non-significant difference. The Mestizo was the most common ethnic group and showed differential ancestry proportions when compared with Afro-Colombians. *Mestizos* displayed a high proportion of European ancestry ( $0.679 \pm 0.119$ ) with low levels of Amerindian ( $0.176 \pm 0.069$ ) and African ( $0.154 \pm 0.117$ ) ancestries. Among Afro-Colombians, the proportion of African ancestry was relatively high ( $0.733 \pm 0.219$ ), but low for the European ( $0.178 \pm 0.168$ ) and the Amerindian ( $0.089 \pm 0.100$ ).

### ***Allelic variants association with dengue***

Every minor allelic frequency was >1% (table 2). Stratification analysis revealed that three allelic variants associated significantly with dengue, two in Afro-Colombians and one in *Mestizos* (table 3). These associations posed one protective factor and another one for risk of dengue in Afro-Colombians while only one single risk factor for *Mestizos*. In Afro-Colombians, the C allele of *IL6R* rs8192284 presented a lower risk, while a higher risk was present in the

A allele of *DC-SIGN* rs7248637. The A allele of *TLR3* rs3775290 displayed the most significant association with the risk of dengue for *Mestizos*. No significant difference was observed between the allelic frequencies in subjects. The data loss rate was minimal.

### Genotypic variants association with dengue

The risk of dengue for specific ancestry contexts was studied by identifying genotypic variants association with dengue. The three loci remained in Hardy-Weinberg equilibrium in all subjects. The frequency of the genotype A/A in *TLR3* was higher in cases than in controls, either with or without ancestry adjustment. The frequency of the genotype C/C in *IL6R* was also higher in cases than in controls, but only when adjusted by the Amerindian component and with no adjustment (table 4). No significant association of rs7248637 genotypes for cases and controls was found. Eight associations with genotypes were found between cases and controls in all subjects.

**Table 2.** Allelic frequencies and Hardy-Weinberg equilibrium for all subjects and after stratification by self-identification

SNP	MAF	n=292	Self-identification		Continental ancestral population*		
			Afro-Colombian n=130	Mestizo n=162	European	Amerindian	African
IL6R rs8192284 <sup>2</sup> n=292 TLR3	C	0.405	0.201	0.479	0.354	0.500	0.062
rs3775290 <sup>2</sup> n=291	A	0.314	0.274	0.390	0.217	0.408	0.102
CD209 rs7248637 <sup>2</sup> n=281	A	0.169	0.247	0.119	0.129	0.110	0.358

SNP: Single nucleotide polymorphism

rs: Reference sequence

MAF: Minor allele frequency

\* MAF is displayed for each ancestral population as reported by NCBI.

**Table 3.** Allelic variants association with dengue. Columns display associations for all subjects after stratification by self-identification.

SNP	Allele	All subjects n=292		Afro-Colombian n=130		Mestizo n=162	
		Cases	Controls	Cases	Controls	Cases	Controls
IL6R rs8192284 n=292	C	0.38	0.32	0.13	0.26	0.51	0.41
OR (95% CI)		1.302 (0.7271-2.333)		0.4253 (0.2040-0.8865)		1.498 (0.8562-2.620)	
p value		0.3737		<b>0.0203</b>		0.1560	
TLR3 rs3775290 n=291	A	0.39	0.30	0.28	0.31	0.45	0.26
OR (95% CI)		1.492 (0.8294-2.683)		0.8656 (0.4710-1.591)		2.329 (1.283-4.226)	
p value		0.1807		0.6418		<b>0.0050</b>	
DC-SIGN rs7248637 n=281	A	0.15	0.16	0.28	0.14	0.10	0.18
OR (95% CI)		0.9265 (0.4305-1.994)		2.389 (1.170-4.879)		0.5062 (0.2209-1.160)	
p value		0.8451		<b>0.0151</b>		0.1030	

SNP: Single nucleotide polymorphism

rs: Reference sequence

OR: Odds ratio in chi-square test

CI: Confidence interval; significant p values are in bold.

**Table 4.** Association of genotypic variants with dengue for all subjects and after ancestry adjustment

<b>SNP</b> <i>IL6R rs8192284</i>						
<b>Genotype</b>	<b>Controls</b>	<b>Cases</b>	<b>Without adjustment</b>	<b>Adjusted European</b>	<b>Adjusted Amerindian</b>	<b>Adjusted African</b>
	<b>n=105</b>	<b>n=187</b>				
	<b>n (%)</b>	<b>n (%)</b>	<b>OR (95% CI)<sup>4</sup></b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>
A/A	47 (44.8)	79 (42.2)	1	1	1	1
A/C	50 (47.6)	75 (40.1)	0.87 (0.53-1.45)	0.75 (0.43-1.31)	0.91 (0.54-1.54)	0.77 (0.44-1.34)
C/C	8 (7.6)	33 (17.6)	2.45 (1.05-5.76)	1.97 (0.81-4.83)	2.52 (1.04-6.09)	2.00 (0.81-4.97)
p-value			<b>0.013</b>	<b>0.032</b>	<b>0.013</b>	<b>0.03</b>

<b>SNP</b> <i>TLR3 rs3775290<sup>2</sup></i>						
<b>Genotype</b>	<b>Controls</b>	<b>Cases</b>	<b>Without adjustment</b>	<b>Adjusted European</b>	<b>Adjusted Amerindian</b>	<b>Adjusted African</b>
	<b>n=105</b>	<b>n=186</b>				
	<b>n (%)</b>	<b>n (%)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>
G/G	51 (48.6)	73 (39.2)	1	1	1	1
G/A	45 (42.9)	81 (43.5)	1.23 (0.74-2.05)	1.20 (0.72-2.01)	1.26 (0.75-2.09)	1.22 (0.73-2.04)
A/A	9 (8.6)	32 (17.2)	2.48 (1.09-5.65)	2.34 (1.02-5.35)	2.49 (1.09-5.66)	2.37 (1.04-5.41)
p-value			<b>0.033</b>	<b>0.048</b>	<b>0.035</b>	<b>0.046</b>

R2 del modelo = 0,55 F(2,213) = 133; p <0,001

<b>SNP</b> <i>DC-SIGN rs7248637</i>						
<b>Genotype</b>	<b>Controls</b>	<b>Cases</b>	<b>Without adjustment</b>	<b>Adjusted European</b>	<b>Adjusted Amerindian</b>	<b>Adjusted African</b>
	<b>n=103</b>	<b>n=178</b>				
	<b>n (%)</b>	<b>n (%)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>	<b>OR (95% CI)</b>
G/G	73 (70.9)	129 (72.5)	1	1	1	1
G/A	28 (27.2)	43 (24.2)	0.87 (0.50-1.52)	0.93 (0.53-1.64)	0.86 (0.49-1.52)	0.93 (0.53-1.65)
A/A	2 (1.9)	6 (3.4)	1.70 (0.33-8.63)	1.87 (0.36-9.61)	1.68 (0.33-8.53)	1.83 (0.36-9.41)
p-value			0.48	0.41	0.48	0.43

SNP: Single nucleotide polymorphism  
rs: Reference sequence  
OR: Odds ratio in chi-square test  
CI: Confidence interval. Significant p values are in bold.

**Table 5.** Association of allelic combinations with dengue for all subjects and after ancestry adjustment

<b>Allelic combination*</b>	<b>Controls n=191</b>	<b>Cases n=101</b>	<b>No adjustment OR (95% CI) p value</b>	<b>Adjusted European OR (95% CI) p value</b>	<b>Adjusted Amerindian OR (95% CI) p value</b>	<b>Adjusted African OR (95% CI) p value</b>
AGG	0.4283	0.2977	1	1	1	1
AAG	0.1555	0.2085	1.68 (0.92-3.07) 0.091	1.64 (0.90-2.99) 0.10	1.68 (0.92-3.06) 0.092	1.65 (0.91-3.00) 0.099
CGG	0.1465	0.1923	1.60 (0.81-3.18) 0.18	1.45 (0.73-2.89) 0.29	1.64 (0.81-3.29) 0.17	1.46 (0.73-2.92) 0.28
CAG	0.1146	0.1476	<b>2.07 (1.06-4.05) 0.033</b>	1.93 (0.97-3.84) 0.062	<b>2.16 (1.09-4.28) 0.028</b>	1.96 (0.98-3.91) 0.057
AGA	0.0688	0.0986	1.96 (0.77-4.97) 0.16	2.13 (0.81-5.63) 0.13	1.93 (0.76-4.91) 0.17	2.09 (0.80-5.45) 0.13
CGA	0.0552	0.0216	0.59 (0.15-2.26) 0.44	0.52 (0.13-2.04) 0.35	0.59 (0.15-2.26) 0.44	0.54 (0.14-2.09) 0.37
AAA	0.031	0.0176	0.92 (0.24-3.56) 0.90	0.93 (0.24-3.58) 0.92	0.89 (0.23-3.47) 0.87	0.95 (0.25-3.64) 0.93
CAA	0	0.0162	4.48 (0.03-766.15) 0.57	4.04 (0.03-523.26) 0.6	4.47 (0.03-725.22) 0.6	3.92 (0.03-448.76) 0.6

\* The order of nucleotides in the allelic combinations is based on the order of polymorphisms in the chromosomes rs8192284 - rs3775290 - rs7248637.  
OR: Odds ratio in chi-square test  
CI: Confidence interval; significant p values are in bold.

### **Variants of allelic combinations associated with dengue**

Two associations between dengue and the allelic combination CAG were observed (table 5). This association was significant for the Amerindian context with and without ancestry adjustment. The CAG combination displayed higher frequency in cases than in controls. No significant association between allelic combinations and dengue was found after adjusting for either European or African ancestries.

### **Discussion**

This study established associations of genetic variants in *IL6R*, *TLR3*, and *DC-SIGN* with dengue after using ancestry or auto-identification control techniques. To the best of our knowledge, this is the first study in America that evaluates the association between dengue and three SNP, namely, rs8192284, rs3775290, and rs7248637, which are located in the encoding genes *IL6R*, *TLR3*, and *DC-SIGN*, respectively. These encoding genes are sensors of the immune system for dengue. The hypothesis evaluated the association of the genetic variants with the susceptibility to suffer dengue in different Colombian ethnic groups or ancestries. To prove this hypothesis, a confirmed dengue group was contrasted using the infection diagnosis in a case-control study of sampled Colombian population (table 1).

We determined African, European, and Amerindian ancestries against Afro-Colombian and *Mestizos*. The ancestral genetic context differences may influence dengue (41,42). In fact, results of this study concur well with Silva (2010) and Galanter (2012) (32,41) by confirming that specific genetic variants may act as markers for risk susceptibility of getting dengue in different ethnic groups or ancestries as shown in previous studies (10,24).

A total of 191 samples of dengue associated strongly with the genetic variants in SNP rs8192284 analyzed for *IL6R*, SNP rs3775290 for *TLR3*, and SNP rs7248637 for *DC-SIGN* (tables 3, 4, and 5). Thus, the effect of the three SNPs on the physiopathology should be strong, since this genetic association was found within a small sample. Evidently, the polymorphisms regulate transcription for both receptors and other genes of the immune system that participate in viral recognition and interferon gamma production as a response to DENV infection (19). Additionally, the risk allele combination for dengue CAG found in *IL6R/TLR3/DC-SIGN* (table 3) was significant without ancestry adjustment and also when controlling for the Amerindian component ( $p < 0.05$ ). A similar trend was found when controlling for both European and African components, although it was not statistically significant. The single most marked observation to emerge from the analysis of allelic combinations was acknowledging the interdependence of all polymorphisms (43).

From the point of view of the analyses for alleles and genotypes, variants associated repeatedly with dengue. A comparison between Afro-Colombian and Mestizo ancestry groups showed that the proportion of the allele C was significantly different ( $p < 0.05$ ) in cases and controls (table 3). The dengue associated with SNP rs8192284 when the genotype C/C was considered before and after controlling for Amerindian ancestry. These repeated associations between variants and dengue could be explained by the likely participation of SNP rs8192284 in the development of joint pain during the acute phase of a number of diseases (6). Additionally, these variants contribute to inflammation amplification among dengue patients via sIL-6/mIL-6 as reported for SNP rs8192284 in other pathologies (26).

The association between dengue and the variants of SNP rs8192284 for *IL6R* has not yet been fully established. Notwithstanding, the strong role of the encoding IL6R in the evolution of other diseases like HIV-1 as regards viral aetiology has been widely addressed (29). In fact, the evidence on the role of the allele C in increasing inflammation for a number of diseases is compelling. For example, allele C strengthens the development of serious illnesses such as arthritis and myeloma (44,45).

The genetic determination of rs8192284 is explained by the enhanced transcription of dendritic cells up to more than 1000 fold for the *IL-6*. Also, the proteolytic receptor binds to the membrane (mIL-6) just in the alanine 358 that is encoded by the allele C and linked to interleukine-6 (28). The association between the variants in genes *IL-6*, *TNFA*, *INFG* and the interleukine-6 levels found in dengue cases has been previously established in Colombia (46). Through linkage disequilibrium, the SNP rs8192284 has also displayed synteny of rs4537545 with other variants in genes *IL6/IL6R/pg130* in a Caucasian Italian population (47). Naturally, the variants in gene *IL-6* weigh the severity of DHF (46). On the other hand, the inflammatory signal from dendritic cells is amplified by the soluble form of the receptor (sIL6-R), which results in remote activation of synoviocytes, chondrocytes, and a number of organs (16,48,49).

With regards to SNP rs3775290 for *TLR3*, the allele A, genotype A/A, and allelic combination CAG were significantly different between cases and controls ( $p < 0.05$ ). As reported by Alagarasu, *et al.*, (24) the evidence we found confirms the contribution of *TLR3* polymorphisms to the development of dengue disease for populations in admixture like the Indian. From the point of view of the variability in those allelic variants, it would appear that there are factors for both risk of and protection against developing dengue (table 3). Several authors have challenged this view on the grounds that these factors could change depending on the context of genetic admixture for the ethnic groups to be compared (31,41,42). However, as put forward by Zapata, *et al.*, (12), the variability in alleles, genotypes, and allelic combinations could be explained by specific differences in the immune response displayed by different ethnic groups. This is consistent with the differences in susceptibility to dengue found between ethnic groups in South America (41). Our results for genotypic distributions and allelic combinations have a number of similarities with these authors (tables 3 and 4). An increasing number of studies have recently found evidence that the SNPrs3775290 is strongly associated with virus-related diseases for ethnic groups with a high proportion of either European or African ancestry (50,51).

The role of SNP rs3775290 in viral aetiology has received much attention in the last few years (52). For example, interferon-stimulated response elements were found whilst studying the promoter sequence of *TLR3 in silico* (30). There is evidence to support the hypothesis that this promoter affects the response of TLR3 and other proinflammatory cytokines. The synergy of the proinflammatory cytokines with TNFA and INFG results in enhanced TLRs production (30). The TLR3 abundance in endosomes of both dendritic and T cells during dengue development is essential for the immune system to counteract the viral infection (23). In addition, the synonym change F459F encoded by SNP rs3775290 is in strong linkage disequilibrium with rs3775291 among Chinese and Polish population (30,51). In both cases, the disease was triggered by a viral infection (HCMV) with severe implications for its development. Evidence of the linkage between rs3775290 and other functional variants that code no synonym changes in *TLR3* for Colombian population is lacking. Further research needs to be carried out to establish whether rs3775290 is in synteny with rs3775291.

As regards *DC-SIGN*, it plays a major role in sensing the viral infection and mediating pathogenesis control (22). The SNP rs7248637 is important owing to its influence on the *DC-SIGN* transcription. The SNP rs7248637 lies in the 3'-untranslated region of the *DC-SIGN* that happens to determine the transcript half-life (53). The development of other viral infections is often rapid when transcript levels decrease due to escape to the immune system (53). The SNP rs7248637 is also involved in the regulation and recognition of a micro-ARN of interference (miARN) (53), which is capable of modulating the risk against getting a disease in response to viral infections for the African population. As anticipated, our results show that rs7248637 greatly relates to dengue development due to its functional effects.

Worldwide, dengue conspicuously associates with a number of variants for *DC-SIGN* (10,21) because of the aforementioned mechanisms. The association of those variants for *DC-SIGN* with dengue is more assertively controlled by ancestry than by self-identification (31,42). *DC-SIGN* supports a variety of primary immune responses. Furthermore, other variants for *DC-SIGN* could decrease the platelet adhesion that leads to thrombocytopenia (9). DENV infection promotes the destruction of both platelets and megakaryocytes *in vitro* (12). It is thus highly likely that DENV infection impairs homeostasis regulation *in vivo*.

This study has given an account of the association between dengue and the variants in SNPs rs8192284 for *IL6R*, rs3775290 for *TLR3*, and rs7248637 for *DC-SIGN*. This means that the genetic component that affects the variability in dengue progression is partially comprised by the variants for the genes *IL6R*, *TLR3*, and *DC-SIGN*. Considerable insight has been gained into genetic markers for dengue prediction, for example, therapeutic targets.

Further work could evaluate the role of other variants in the antiviral response associated with IFNs production through *TLR3* (4). Zapata, *et al.*, (12) have shown that enhanced production of interferon gamma favors the increase in megakaryocytes that take part in the possible development of dengue coagulopathies. Additional work may look at the association of dengue with all the variants from the polymorphisms in the entire *TLRs* family, especially with *TLRs3/4/7/9*. More functional studies are also needed to establish the role of each *TLR* in the physiopathology and severity of dengue in admixed populations such as the Colombian one.

Our findings may have a number of medical applications. One could be preventing dengue disease in African, European and Amerindian ancestry contexts or ethnic groups by looking at SNP frequencies associated with the risk of getting dengue, which can be assessed through the count of risk alleles in populations or individuals. This knowledge could lead to designing strategies based on non-genetic risk factors such as the use of bed nets and mosquito population control. A second application could be long-term evaluations of associations between the *IL6R*, *TLR3*, and *DC-SIGN* variants and other phenotypes related to DENV infection, such as the progression of hemorrhagic dengue, plasmatic extravasation, and cytokines production by genic expression assays, as well as other functional molecular studies.

### Acknowledgements

We are indebted to R. Ramírez for his valuable help with the laboratory analysis. We warmly thank D. Ibargüen from the *Laboratorio de Salud Pública* in Chocó for his help with sampling. Thanks are also due to the *Escuela de Microbiología* at *Universidad de Antioquia* for their technical assistance.

## References

1. **Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al.** Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. *N Engl J Med.* 2015;373:1195-206. <https://doi.org/10.1056/NEJMoa1506223>
2. **Salles TS, da Encarnacao Sa-Guimaraes T, de Alvarenga ES, Guimaraes-Ribeiro V, de Meneses MD, de Castro-Salles PF, et al.** History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: A review. *Parasit Vectors.* 2018;11:264. <https://doi.org/10.1186/s13071-018-2830-8>
3. **Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al.** The global distribution and burden of dengue. *Nature.* 2013;496:504-7. <https://doi.org/10.1038/nature12060>
4. **Mangold KA, Reynolds SL.** A review of dengue fever: A resurging tropical disease. *Pediatr Emerg Care.* 2013;29:665-9. <https://doi.org/10.1097/PEC.0b013e31828ed30e>
5. **Cruz CD, Forshey BM, Juárez DS, Guevara C, Leguia M, Kochel TJ, et al.** Molecular epidemiology of American/Asian genotype DENV-2 in Perú. *Infect Genet Evol.* 2013;18:220-8. <https://doi.org/10.1016/j.meegid.2013.04.029>
6. **World Health Organization.** Dengue: Guidelines for diagnosis, treatment, prevention and control. Geneva: WHO; 2009. p. 3-17.
7. **Sun P, Kochel TJ.** The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. *Scientific World Journal.* 2013;2013:1-11. <https://doi.org/10.1155/2013/843469>
8. **World Health Organization.** Dengue haemorrhagic fever. Diagnosis, treatment, prevention and control. Geneva: WHO; 1997. p. 12-23.
9. **Alagarasu K, Damle I, Bachal R, Mulay A, Shah P, Dayaraj C.** Association of promoter region polymorphisms of CD209 gene with clinical outcomes of dengue virus infection in Western India. *Infect Genet Evol.* 2013;17:239-42. <https://doi.org/10.1016/j.meegid.2013.04.024>
10. **Pabalan N, Chaisri S, Tabunhan S, Phumyen A, Jarjanazi H, Steiner TS.** Associations of DC-SIGN (CD209) promoter -336G/A polymorphism (rs4804803) with dengue infection: A systematic review and meta-analysis. *Acta Trop.* 2018;177:186-93. <https://doi.org/10.1016/j.actatropica.2017.10.017>
11. **Liu P, Ridilla M, Patel P, Betts L, Gallichotte E, Shahidi L, et al.** Beyond attachment: Roles of DC-SIGN in dengue virus infection. *Traffic.* 2017;18:218-31. <https://doi.org/10.1111/tra.12469>
12. **Zapata JC, Cox D, Salvato MS.** The role of platelets in the pathogenesis of viral hemorrhagic fevers. *PLoS Negl Trop Dis.* 2014;8:e2858. <https://doi.org/10.1371/journal.pntd.0002858>
13. **Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, et al.** Autoimmunity in dengue pathogenesis. *J Formos Med Assoc.* 2013;112:3-11. <https://doi.org/10.1016/j.jfma.2012.11.006>
14. **Nielsen DG.** The relationship of interacting immunological components in dengue pathogenesis. *Virology.* 2009;6:211. <https://doi.org/10.1186/1743-422X-6-211>
15. **Juffrie M, van Der Meer GM, Hack CE, Haasnoot K, Sutaryo S, Veerman AJ, et al.** Inflammatory mediators in dengue virus infection in children: Interleukin-8 and its relationship to neutrophil degranulation. *Infect Immun.* 2000;68:702-7. <https://doi.org/10.1128/IAI.68.2.702-707.2000>
16. **Ferreira RC, Freitag DF, Cutler AJ, Howson JM, Rainbow DB, Smyth DJ, et al.** Functional IL6R 358Aa allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. *PLoS Genet.* 2013;9:e1003444. <https://doi.org/10.1371/journal.pgen.1003444>
17. **Marín V, Montero-Julián FA, Gres S, Boulay V, Bongrand P, Farnarier C, et al.** The IL-6-soluble IL-6R $\alpha$  autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: An experimental model involving thrombin. *J Immunol.* 2001;167:3435-42. <https://doi.org/10.4049/jimmunol.167.6.3435>
18. **Torres S, Hernández JC, Giraldo D, Arboleda M, Rojas M, Smit JM, et al.** Differential expression of Toll-like receptors in dendritic cells of patients with dengue during early and late acute phases of the disease. *PLoS Negl Trop Dis.* 2013;7:e2060. <https://doi.org/10.1371/journal.pntd.0002060>

19. **Sessions OM, Tan Y, Goh KC, Liu Y, Tan P, Rozen S, et al.** Host cell transcriptome profile during wild-type and attenuated dengue virus infection. *PLoS Negl Trop Dis.* 2013;7:1-12. <https://doi.org/10.1371/journal.pntd.0002107>
20. **Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, et al.** A variant in the CD209 promoter is associated with severity of dengue disease. *Nat Genet.* 2005;37:507-13. <https://doi.org/10.1038/ng1550>
21. **Wang L, Chen RF, Liu JW, Lee IK, Lee CP, Kuo HC, et al.** DC-SIGN (CD209) Promoter -336 A/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. *PLoS Negl Trop Dis.* 2011;5:e934. <https://doi.org/10.1371/journal.pntd.0000934>
22. **Moumad K, Lascorz J, Bevier M, Khyatti M, Ennaji MM, Benider A, et al.** Genetic polymorphisms in host innate immune sensor genes and the risk of nasopharyngeal carcinoma in North Africa. *G3 (Bethesda).* 2013;3:971-7. <https://doi.org/10.1534/g3.112.005371>
23. **Kawai T, Akira S.** The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. *Nat Immunol.* 2010;11:373-84. <https://doi.org/10.1038/ni.1863>
24. **Alagarasu K, Bachal RV, Memane RS, Shah PS, Cecilia D.** Polymorphisms in RNA sensing toll like receptor genes and its association with clinical outcomes of dengue virus infection. *Immunobiology.* 2015;220:164-8. <https://doi.org/10.1016/j.imbio.2014.09.020>
25. **Sironi M, Biasin M, Cagliani R, Forni D, De Luca M, Saulle I, et al.** A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. *J Immunol.* 2012;188:818-23. <https://doi.org/10.4049/jimmunol.1102179>
26. **Lamas JR, Rodríguez-Rodríguez L, Tornero-Esteban P, Villafuertes E, Hoyas J, Abasolo L, et al.** Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis. *Cytokine.* 2013;61:720-3. <https://doi.org/10.1016/j.cyto.2012.12.025>
27. **Reich D, Patterson N, Ramesh V, De Jager PL, McDonald GJ, Tandon A, et al.** Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. *Am J Hum Genet.* 2007;80:716-26. <https://doi.org/10.1086/513206>
28. **Rose-John S.** IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6. *Int J Biol Sci.* 2012;8:1237-47. <https://doi.org/10.7150/ijbs.4989>
29. **Barcellini W, Rizzardì GP, Poli G, Tambussi G, Velati C, Meroni PL, et al.** Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. *AIDS Res Hum Retroviruses.* 1996;12:325-31. <https://doi.org/10.1089/aid.1996.12.325>
30. **Yang HY, Lee HS, Lee CH, Fang WH, Chen HC, Salter DM, et al.** Association of a functional polymorphism in the promoter region of TLR-3 with osteoarthritis: A two-stage case-control study. *J Orthop Res.* 2013;31:680-5. <https://doi.org/10.1002/jor.22291>
31. **Chacón-Duque JC, Adhikari K, Avendaño E, Campo O, Ramírez R, Rojas W, et al.** African genetic ancestry is associated with a protective effect on dengue severity in Colombian populations. *Infect Genet Evol.* 2014;27C:89-95. <https://doi.org/10.1016/j.meegid.2014.07.003>
32. **Galanter JM, Fernández-López JC, Gignoux CR, Barnholtz-Sloan J, Fernández-Rozadilla C, Via M, et al.** Development of a panel of genome-wide ancestry informative markers to study admixture throughout the Americas. *PLoS Genet.* 2012;8:1-16. <https://doi.org/10.1371/journal.pgen.1002554>
33. **Restrepo BN, Piedrahita LD, Agudelo IY, Parra-Henao G, Osorio JE.** Frequency and clinical features of dengue infection in a schoolchildren cohort from Medellín, Colombia. *J Trop Med.* 2012;2012:120496. <https://doi.org/10.1155/2012/120496>
34. **Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV.** Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. *J Clin Microbiol.* 1992;30:545-51.
35. **Harris E, Roberts TG, Smith L, Selle J, Kramer LD, Valle S, et al.** Typing of dengue viruses in clinical specimens and mosquitoes by single-tube multiplex reverse transcriptase PCR. *J Clin Microbiol.* 1998;36:2634-9.
36. **Sambrook J, Russell DW.** Purification of nucleic acids by extraction with phenol:chloroform. *CSH Protoc.* 2006. <https://doi.org/10.1101/pdb.prot4455>

37. **Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, et al.** Estimating African American admixture proportions by use of population-specific alleles. *Am J Hum Genet.* 1998;63:1839-51. <https://doi.org/10.1086/302148>
38. **Sole X, Guino E, Valls J, Iniesta R, Moreno V.** SNPStats: A web tool for the analysis of association studies. *Bioinformatics.* 2006;22:1928-9. <https://doi.org/10.1093/bioinformatics/btl268>
39. **McKeigue PM, Carpenter JR, Parra EJ, Shriver MD.** Estimation of admixture and detection of linkage in admixed populations by a Bayesian approach: Application to African-American populations. *Ann Hum Genet.* 2000;64:171-86. <https://doi.org/10.1017/S000348000008022>
40. **Chua KB, Mustafa B, Abdul-Wahab AH, Chem YK, Khairul AH, Kumarasamy V, et al.** A comparative evaluation of dengue diagnostic tests based on single-acute serum samples for laboratory confirmation of acute dengue. *Malays J Pathol.* 2011;33:13-20.
41. **Silva LK, Blanton RE, Parrado AR, Melo PS, Morato VG, Reis EA, et al.** Dengue hemorrhagic fever is associated with polymorphisms in JAK1. *Eur J Hum Genet.* 2010;18:1221-7. <https://doi.org/10.1038/ejhg.2010.98>
42. **Blanton RE, Silva LK, Morato VG, Parrado AR, Dias JP, Melo PR, et al.** Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population. *Eur J Hum Genet.* 2008;16:762-5. <https://doi.org/10.1038/ejhg.2008.4>
43. **Harapan H, Fajar JK, Wahyuniati N, Anand JR, Nambaru L, Jamil KF.** Non-HLA gene polymorphisms and their implications on dengue virus infection. *Egyptian Journal of Medical Human Genetics.* 2013;14:1-11. <https://doi.org/10.1016/j.ejmhg.2012.08.003>
44. **Li Y, Du Z, Wang X, Wang G, Li W.** Association of IL-6 promoter and receptor polymorphisms with multiple myeloma risk: A systematic review and meta-analysis. *Genet Test Mol Biomarkers.* 2016;20:587-96. <https://doi.org/10.1089/gtmb.2015.0169>
45. **De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A.** Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. *J Clin Invest.* 1994;93:2114-9. <https://doi.org/10.1172/JCI117206>
46. **Avendaño-Tamayo E, Campo O, Chacón-Duque J, Ramírez R, Rojas W, Agudelo-Flórez P, et al.** Variantes en los genes TNFA, IL6 e IFNG asociadas con la gravedad del dengue en una muestra de población colombiana. *Biomédica.* 2017;37:485-97. <https://doi.org/10.7705/biomedica.v37i4.3305>
47. **Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, et al.** Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman disease and is associated with increased soluble interleukin-6 receptor levels. *PLoS One.* 2013;8:e54610. <https://doi.org/10.1371/journal.pone.0054610>
48. **Wang XJ, Taga T, Yoshida K, Saito M, Kishimoto T, Kikutani H.** gp130, the cytokine common signal-transducer of interleukin-6 cytokine family, is downregulated in T cells in vivo by interleukin-6. *Blood.* 1998;91:3308-14.
49. **Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, et al.** Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. *Science.* 1988;241:825-8. <https://doi.org/10.1126/science.3136546>
50. **Zayed RA, Omran D, Mokhtar DA, Zakaria Z, Ezzat S, Soliman MA, et al.** Association of toll-like receptor 3 and toll-like receptor 9 single nucleotide polymorphisms with hepatitis c virus infection and hepatic fibrosis in Egyptian patients. *Am J Trop Med Hyg.* 2017;96:720-6. <https://doi.org/10.4269/ajtmh.16-0644>
51. **Studzinska M, Jablonska A, Wisniewska-Ligier M, Nowakowska D, Gaj Z, Lesnikowski ZJ, et al.** Association of TLR3 L412F polymorphism with cytomegalovirus infection in children. *PLoS One.* 2017;12:e0169420. <https://doi.org/10.1371/journal.pone.0169420>
52. **Goktas EF, Bulut C, Goktas MT, Ozer EK, Karaca RO, Kinikli S, et al.** Investigation of 1377C/T polymorphism of the Toll-like receptor 3 among patients with chronic hepatitis B. *Can J Microbiol.* 2016;62:617-22. <https://doi.org/10.1139/cjm-2016-0129>
53. **Lu S, Bevier M, Huhn S, Sainz J, Lascorz J, Pardini B, et al.** Genetic variants in C-type lectin genes are associated with colorectal cancer susceptibility and clinical outcome. *Int J Cancer.* 2013;133:2325-33. <https://doi.org/10.1002/ijc.28251>